Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Leukemia, Myeloid, Acute 8Triple Negative Breast Neoplasms 4Leukemia 3Cardiotoxicity 2Thrombocythemia, Essential 1Stomach Neoplasms 1Primary Myelofibrosis 1Primary Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms, Second Primary 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1HER2-negative Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1Biliary Tract Neoplasms 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Anthracyclines × Clear all
NCT01019616 2021-11-29

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Peking University

Phase 3 Unknown
400 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡